3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
6
Phase 3
1
Phase 1
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Melanoma
4
Neoplasms
2
Leukemia, Myeloid, Acute
2
Breast Neoplasms
2
Sepsis
1
Sarcoma
1
Rhabdomyosarcoma
1
Prostatic Neoplasms
1
Pathologic Complete Response
1
Neutropenia
1
Neuroblastoma
1
Neoplasm Metastasis
1
Multiple Myeloma
1
Malignant mesenchymal tumor
1
Lymphoma, Non-Hodgkin
1
Lymphoma
1
Leukemia, Myeloid, Chronic-Phase
1
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
1
Hematologic Diseases
1
Graft vs Host Disease
1
Gliosarcoma
1
Glioblastoma
1
Fever
1
Carcinoma, Renal Cell
1
Brain Neoplasms
1
Interventions
Leucovorin
22
Fluorouracil
22
Paclitaxel
21
Gemcitabine
21
Docetaxel
21
Capecitabine
21
Irinotecan
16
Carboplatin
15
Radiosurgery
14
Oxaliplatin
13
Cisplatin
13
Bevacizumab
13
Zoledronic Acid
12
pembrolizumab
11
Radiotherapy
11
Fulvestrant
11
palbociclib
9
Pemetrexed
9
Drug Therapy
9
130-nm albumin-bound paclitaxel
9
Surgical Procedures, Operative
7
Letrozole
7
Ibandronic Acid
7
abemaciclib
6
Trastuzumab
6
Prednisone
6
Vinorelbine
5
Folfox protocol
5
Floxuridine
5
Doxorubicin
5
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 3
×
Neoplasm Metastasis
×
Granulocyte-Macrophage Colony-Stimulating Factor
×
Clear all
NCT01322490
2019-09-04
Prospect
Bavarian Nordic
Phase 3
Completed
1,297 enrolled
16 charts